PPD expands patient access to clinical trials via collaboration with cancer center

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/cameravit)
(Image: Getty/cameravit)

Related tags: Ppd, Cancer, Hospital, trial recruitment, Clinical trial

PPD’s patient enrollment business expands access to cancer patients treated in the community setting as part of a new collaboration with a hospital and outpatient center network.

PPD’s Accelerated Enrollment Solutions (AES) business unit is collaborating with the Cancer Treatment Centers of America (CTCA) to deploy its Optimal Just-in-Time (JIT) patient recruitment methodology at CTCA managed sites.

“Just-in-Time is an innovative methodology through which we expand clinical trial access to the more than 85% of US cancer patients who are treated in the community setting,”​ said Krystyna Kowalczyk, chief operating officer for Optimal service offerings.

The collaboration is focused on providing local care, cross-specialty patient services, and access to clinical trials through the patient’s local treating physician, she told us.

Kowalczyk said the goal is “to allow the patient and physician to make choices that are not dependent upon where a patient lives.”

“We already have seen an increase in minority access to trials through our collaboration with CTCA and hope to make this type of access the new ‘norm’ for cancer patients across the country,”​ she said.

According to the company, the JIT approach identifies patients first before sites are activated, which results in zero non-enrolling sites.

PPD earlier this month announced​ that AES will be supporting clinical trial enrollment of participants in the Synexus HealthyMinds Registry (HMR), which aims to register 30,000 adults for a five-year study.

The collaboration initially aims to register 30,000 adults aged 50 or older in the US without signs of dementia for a five-year study that will examine lifestyle and genetic risk factors affecting cognitive function.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars